Frazier Life Sciences Management’s Arvinas ARVN Stock Holding History

Frazier Life Sciences Management’s Portfolio ARVN Stock Details ARVN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-285,331	Closed	-$5.47M	–	49
2024 Q4	$5.47M	Hold	285,331	–	–	0.23%	46
2024 Q3	$7.03M	Hold	285,331	–	–	0.28%	46
2024 Q2	$7.6M	Hold	285,331	–	–	0.36%	41
2024 Q1	$11.8M	Hold	285,331	–	–	0.5%	40
2023 Q4	$11.7M	Hold	285,331	–	–	0.63%	38
2023 Q3	$5.6M	Hold	285,331	–	–	0.37%	42
2023 Q2	$7.08M	Hold	285,331	–	–	0.42%	37
2023 Q1	$7.8M	Hold	285,331	–	–	0.56%	34
2022 Q4	$9.76M	Hold	285,331	–	–	0.61%	33
2022 Q3	$12.7M	Hold	285,331	–	–	0.98%	25
2022 Q2	$12M	Buy	285,331 +15,000	+6%	+$753K	1.13%	23
2022 Q1	$18.2M	Buy	+270,331	New	+$18.4M	1.55%	20

Other funds holding ARVN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Pfizer New York $170M AUM 191.09% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Frazier Life Sciences Management's ARVN Position: Q1 2025 in Review

Frazier Life Sciences Management sold out of Arvinas (ARVN) in Q1 2025, closing a stake of 285,331 shares — an estimated $5.47M sold.

Frazier Life Sciences Management first reported a position in ARVN in Q1 2022 and held it in 12 quarters. The position peaked at $18.2M in Q1 2022. 215 funds tracked by Wall St. Rank hold ARVN as of Q1 2025.

Frazier Life Sciences Management reported no remaining Arvinas position as of Q1 2025 after selling out during the quarter.
Frazier Life Sciences Management sold 285,331 Arvinas shares in Q1 2025, an estimated $5.47M.
Frazier Life Sciences Management first reported a position in Arvinas in Q1 2022 and held it in 12 quarters.
Frazier Life Sciences Management's Arvinas position peaked at $18.2M in Q1 2022.
215 funds tracked by Wall St. Rank held Arvinas as of Q1 2025.

Based on Frazier Life Sciences Management's 13F filing for Q1 2025, filed 15 May 2025.